Stay updated with breaking news from Nasdaq Clrb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Oppenheimer cut their price target on Cellectar Biosciences from $11.00 to $10.00 in a research note on Friday, May 5th. Get Our Latest […]
FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the...
StockNews.com assumed coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, Oppenheimer decreased their price target on shares of Cellectar Biosciences from $11.00 to $10.00 in a report on Friday, May 5th. […]
StockNews.com assumed coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a report issued on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Oppenheimer cut their price target on shares of Cellectar Biosciences from $11.00 to $10.00 in a research report on Friday, May 5th. Cellectar Biosciences […]
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 127,700 shares, an increase of 18.5% from the June 15th total of 107,800 shares. Approximately 1.4% of the shares of the company are sold short. Based […]